NCT04203992 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Boardley I, Smith AL, Mills JP, Grix J, Wynne C
, & Wilkins L. Development of Moral Disengagement and Self-Regulatory Efficacy Assessments Relevant to Doping in Sport and Exercise. SportRxiv, 12 Oct. 2017. Web.
Chan DK, Dimmock JA, Donovan RJ, Hardcastle S, Lentillon-Kaestner V, Hagger MS
Self-determined motivation in sport predicts anti-doping motivation and intention: a perspective from the trans-contextual model. J Sci Med Sport. 2015 May;18(3):315-22. doi: 10.1016/j.jsams.2014.04.001. Epub 2014 Apr 13.
Goulet C, Valois P, Buist A, Côté M
Predictors of the use of performance-enhancing substances by young athletes. Clin J Sport Med. 2010 Jul;20(4):243-8. doi: 10.1097/JSM.0b013e3181e0b935.
Nicholls AR, Levy AR, Meir R, Sanctuary C, Jones L, Baghurst T, Thompson MA, Perry JL
The development and validation of the Adolescent Sport Drug Inventory (ASDI) among athletes from four continents. Psychol Assess. 2019 Nov;31(11):1279-1293. doi: 10.1037/pas0000750. Epub 2019 Jul 18.

TRUE CHAMPION: An Educational Videogame Intervention for the Prevention of Doping and Supplement Abuse in Teenage Athletes

Clinical trial NCT04203992 - References